Search Login Register

Somatostatin (Somatotropin Release-Inhibiting Factor) Summary

Description: A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.

Also Known As: Somatotropin Release-Inhibiting Factor; Somatotropin Release Inhibiting Hormone; SRIH-14; Somatofalk; Somatostatin, Cyclic Show All >>

Networked: 7049 relevant articles (563 outcomes, 902 trials/studies) for this Bio-Agent

Key Diseases for which Somatostatin is Relevant

  1. Neoplasms (Cancer) : 95 outcomes 131 studies in 1491 results
  2. Acromegaly : 79 outcomes 61 studies in 571 results
  3. Hemorrhage : 61 outcomes 84 studies in 297 results
  4. Carcinoid Tumor (Carcinoid) : 42 outcomes 26 studies in 356 results
  5. Pancreatitis : 32 outcomes 54 studies in 190 results
Show All >>

Drugs Related to Somatostatin

  1. Octreotide (Sandostatin)
  2. lanreotide (Somatuline)
  3. Somatostatin Receptors (Somatostatin Receptor)
  4. Hormones
  5. Insulin (Novolin)
  6. Growth Hormone (Somatotropin)
  7. Insulin-Like Growth Factor I (IGF-1)
  8. Dopamine Agonists (Dopamine Agonist)
  9. Vasopressins (Vasopressin)
  10. pegvisomant
Show All >>

Therapies Related to Somatostatin

  1. Drug Therapy (Chemotherapy)
  2. Sclerotherapy
  3. Radiotherapy
  4. Total Parenteral Nutrition
  5. Injections
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.